Target intelligence / Profile preview

Aggregated paired helical filament tau (PHF-tau) (PHF-tau)

Target
PHF-tau
Molecular classification
Microtubule-associated protein, Protein aggregate, Misfolded protein
01

Overview

Aggregated paired helical filament tau (PHF-tau), which forms neurofibrillary tangles (NFTs), is a primary pathological hallmark of Alzheimer's disease and various other neurodegenerative disorders known as tauopathies. In a healthy state, tau is a soluble protein that promotes microtubule assembly and stability within axons; however, pathological hyperphosphorylation causes tau to detach from microtubules and misfold into insoluble filaments. These filaments aggregate into NFTs, which disrupt cellular transport mechanisms and eventually lead to synaptic loss and neuronal death. Therapeutic interventions targeting PHF-tau include monoclonal antibodies designed to intercept the 'seeding' of tau between neurons and small molecules intended to inhibit the aggregation process or promote the clearance of existing tangles. Because the density and distribution of these aggregates correlate strongly with cognitive decline, they serve as critical targets for both disease-modifying therapies and diagnostic neuroimaging.

Other names
Neurofibrillary tanglesNFTsTau aggregatesHyperphosphorylated tau aggregatesPaired helical filamentsMisfolded tau protein
02

Mechanism of action

Inhibition of tau aggregation, disaggregation of existing paired helical filaments, antibody-mediated clearance of extracellular tau seeds to prevent trans-synaptic spreading, and selective binding for PET imaging visualization.

03

Biological functions

Microtubule stabilization (physiological)Axonal transport regulation (physiological)Proteotoxicity (pathological)Seeding and spreading of proteinopathy (pathological)
04

Disease associations

Alzheimer's diseaseProgressive supranuclear palsyCorticobasal degenerationPick's diseaseChronic traumatic encephalopathyFrontotemporal dementiaTauopathy
05

Safety considerations

Off-target binding to monoamine oxidase (MAO-A/B) in PET tracersPotential for inflammatory response or ARIA-like events with immunotherapyDifficulty in crossing the blood-brain barrier for large moleculesRisk of releasing toxic oligomeric seeds during disaggregation processes
06

Interacting drugs

Flortaucipir F-18

9 more in the full profile.

07

Biomarkers

Tau PET imaging (e.g., [18F]flortaucipir)CSF phosphorylated-tau (p-tau181, p-tau217, p-tau231)Plasma p-tau217CSF total tau (t-tau)

Beyond the preview

Go deeper on Aggregated paired helical filament tau (PHF-tau) (PHF-tau).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aggregated paired helical filament tau (PHF-tau) (PHF-tau).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call